Drug Profile
COVID-19 infection therapeutic - Charite University of Medicine Berlin/Pluri
Latest Information Update: 13 Mar 2023
Price :
$50
*
At a glance
- Originator Charite - Universitatsmedizin Berlin; Pluristem Therapeutics
- Developer Pluri
- Class Anti-inflammatories; Antivirals; Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown COVID 2019 infections
Most Recent Events
- 08 Jul 2021 Pluristem Therapeutics withdraw collaborative research agreement with Innovare R&D for a phase II trial for SARS-COV-2 acute respiratory disease in Mexico
- 29 Dec 2020 Pluristem Therapeutics enters into collaborative research agreement with Innovare R&D for phase II trial of PLX cell product candidates for SARS-COV-2 acute respiratory disease in Mexico
- 21 Jul 2020 Pluristem Therapeutics plans a phase II trial for COVID-2019 in Germany